JPMorgan discusses with management Setrusumab considerations heading into ORBIT/COSMIC and provides updates on YE25 on a conference call to be held on July 14 at 11:30 am hosted by JPMorgan. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx price target lowered to $79 from $80 at BofA
- Positive Outlook on Ultragenyx Pharmaceutical Despite Setback with UX111 Approval
- Ultragenyx announces Health Canada extended approval of Evkeeza
- Ultragenyx price target lowered to $55 from $65 at Morgan Stanley
- Ultragenyx falls 4% to $28.41 after FDA rejection letter for gene therapy